natgillin/translations-raw huggingface dataset:
However, the chemical and physical in-use stability has been demonstrated for 8 hours at 5°C and 25°C stored in the original vial and/or a syringe. 
Kemična in fizikalna stabilnost zdravila sta bili dokazani za 8 ur pri temperaturah 5 °C in 25 °C, če ga shranjujemo v originalni viali in/ali injekcijski brizgi.
You will receive 4 cycles (12 weeks). 
Prejeli boste 4 cikle zdravljenja (12 tednov).
Hospira 1 mg, 2.5 mg, 3 mg and 3.5 mg. 
Bortezomib Hospira 1 mg, 2,5 mg, 3 mg in 3,5 mg.
A Phase II, single-arm activity, safety, and pharmacokinetic trial conducted by the Children's Oncology Group assessed the activity of the addition of bortezomib to multi agent re induction chemotherapy in paediatric and young adult patients with lymphoid malignancies (pre-B cell acute lymphoblastic leukemia [ALL], T-cell ALL, and T-cell lymphoblastic lymphoma [LL]). 
V farmakokinetičnem preskušanji glede varnosti in učinkovitosti faze II z eno skupino, ki jo je izvedla Skupina za otroško onkologijo (COG - Children's Oncology Group), so ocenili delovanje bortezomiba, ki so ga dodali k ponovno uvedeni indukcijski kemoterapiji z več zdravili pri pediatričnih in mladih odraslih bolnikih z limfatičnimi malignomi (s pre-B-celično akutno limfoblastno levkemijo [ALL], T-celično ALL in T-celičnim limfoblastnim limfomom [LL]).
Once the symptoms of the toxicity have resolved, Bortezomib Hospira treatment may be re-initiated at a 25% reduced dose (1.3 mg/m2 reduced to 1.0 mg/m2, 1.0 mg/m2 reduced to 0.7 mg/m2). 
Ko simptomi toksičnosti minejo, lahko zdravljenje z zdravilom Bortezomib Hospira ponovno uvedete, vendar s 25 % manjšim odmerkom (1,3 mg/m zmanjšano na 1,0 mg/m2; 1,0 mg/m2 zmanjšano na 0,7 mg/m2 telesne površine).
EXP The reconstituted solution should be used immediately after preparation. 
EXP Rekonstituirano raztopino je treba uporabiti takoj po pripravi.
You may also be given bortezomib together with the medicines pegylated liposomal doxorubicin or dexamethasone. 
Bortezomib boste lahko prejeli tudi skupaj z zdraviloma pegilirani liposomski doksorubicin ali deksametazon.
Note: An OR > 1 indicates an advantage for bortezomib-containing induction therapy. 
Opomba: OR > 1 kaže na prednost uvajalnega zdravljenja z bortezomibom.
Patients experiencing new or worsening peripheral neuropathy should undergo neurological evaluation and may require a change in the dose, schedule or route of administration to subcutaneous (see section 4.2). 
Pri bolnikih, pri katerih se periferna nevropatija pojavi prvič ali se obstoječa periferna nevropatija poslabša, je treba opraviti nevrološko oceno in po potrebi prilagoditi odmerek, shemo odmerjanja ali spremeniti način dajanja zdravila v subkutano injiciranje (glejte poglavje 4.2).
This includes any side effects not listed in this leaflet. 
Posvetujte se tudi, če opazite katerekoli neželene učinke, ki niso navedeni v tem navodilu.
Type I glass 10 ml vial with a rubber stopper and an aluminium seal containing 2.5 mg, 3 mg or 3.5 mg bortezomib. 
10 ml steklena viala, steklo tipa I, z zamaškom iz gume in aluminijasto zaporko; vsebuje 2,5 mg, 3 mg ali 3,5 mg bortezomiba.
When bortezomib is given in combination with thalidomide you must follow the pregnancy prevention programme for thalidomide (see package leaflet for thalidomide). 
Če jemljete bortezomib v kombinaciji s talidomidom, morate upoštevati program za preprečevanje nosečnosti, ki velja za talidomid (glejte navodilo za uporabo talidomida).
In the Phase III study comparing bortezomib administered intravenously versus subcutaneously, the incidence of Grade ≥ 2 peripheral neuropathy events was 24% for the subcutaneous injection group and 41% for the intravenous injection group (p=0.0124). 
V preskušanju faze III z bortezomibom, ki je primerjalo intravensko in subkutano dajanje bortezomiba, je bila pojavnost dogodkov periferne nevropatije stopnje ≥ 2 v skupini, ki je prejemala zdravilo subkutano, 24 %, v skupini, ki je prejemala zdravilo intravensko, pa 41 % (p = 0,0124).
Common Rash*, Pruritus*, Erythema, Dry skin 
Pogosti izpuščaj*, srbenje*, eritem, suha koža
Potentially immunocomplex-mediated reactions, such as serum-sickness-type reaction, polyarthritis with rash and proliferative glomerulonephritis have been reported uncommonly. 
Občasno so poročali o reakcijah, povzročenih z imunskimi kompleksi, kot so reakcija tipa serumske bolezni, poliartritis z izpuščajem in proliferativni glomerulonefritis.
CR=Complete Response; CRu=Complete Response unconfirmed; PR=Partial Response; CI=Confidence Interval, HR=Hazard Ratio; OR=Odds Ratio; ITT=Intent to Treat 
CR = popoln odziv; CRu = nepotrjen popoln odziv; PR = delni odziv; IZ = interval zaupanja, HR = razmerje ogroženosti; OR = razmerje obetov; ITT = populacija z namenom zdravljenja
Incidence of PN (%) 
pojavnost PN (%)
PRES is a rare, often reversible, rapidly evolving neurological condition, which can present with seizure, hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances. 
Pri bolnikih, ki so prejemali bortezomib, so poročali o PRES. PRES je redka, pogosto reverzibilna nevrološka motnja, ki se razvije hitro in se lahko kaže z epileptičnimi napadi, hipertenzijo, glavoboli, letargijo, zmedenostjo, slepoto in drugimi motnjami vida ter nevrološkimi motnjami.
Uncommon Hyperbilirubinaemia*, Protein analyses abnormal*, Weight increased, Blood test abnormal*, C-reactive protein increased 
Občasni hiperbilirubinemija*, nenormalni izvidi analiz proteinov*, zvečana telesna masa, nenormalni izvidi krvnih preiskav*, zvišana koncentracija C-reaktivnega proteina
Vision abnormal* 
Pogosti nenormalen vid*
Very Common Nausea and vomiting symptoms*, Diarrhoea*, Stomatitis*, Constipation 
Zelo pogosti simptomi navzee in bruhanja *, diareja*, stomatitis*, zaprtje
In a study in previously untreated mantle cell lymphoma patients, 42.9% and 10.4% of patients exposed to bortezomib were in the range 65-74 years and ≥ 75 years of age, respectively. 
V preskušanju z bortezomibom pri bolnikih, pri katerih limfom plaščnih celic še ni bil zdravljen, je bilo 42,9% bolnikov starih 65-74 let in 10,4 % bolnikov starih ≥ 75 let.
Table 5: Dose adjustments during treatment for patients with previously untreated mantle cell lymphoma Toxicity 
Preglednica 5: Prilagajanje odmerkov med zdravljenjem pri bolnikih s predhodno nezdravljenim limfomom plaščnih celic
When toxicity resolves re-initiate Bortezomib Hospira treatment and reduce dose to 0.7 mg/m2 once per week. 
Nato ponovno sledi uvedba zdravljenja z zdravilom Bortezomib Hospira in zmanjšanje odmerka na 0,7 mg/m2 enkrat na teden.
A drug-drug interaction study assessing the effect of ketoconazole, a potent CYP3A4 inhibitor, on the pharmacokinetics of bortezomib (injected intravenously), showed a mean bortezomib AUC increase of 35% (CI90% [1.032 to 1.772]) based on data from 12 patients. 
Študija medsebojnega delovanja zdravil, ki je ocenjevala učinek ketokonazola, močnega zaviralca CYP3A4, na famakokinetiko bortezomiba (danega intravensko), je na osnovi podatkov 12 bolnikov pokazala povprečen dvig AUC bortezomiba za 35 % (IZ90% (1,032 do 1,772)).
The pharmacokinetics of bortezomib are not influenced in patients with mild to moderate renal impairment (Creatinine Clearance [CrCL] > 20 ml/min/1.73 m2); therefore, dose adjustments are not necessary for these patients. 
Pri bolnikih z blago do zmerno okvaro ledvic (očistek kreatinina [CrCL] > 20 ml/min/1,73 m farmakokinetika bortezomiba ni spremenjena, zato pri njih prilagajanje odmerka ni potrebno.
Both in patients who were refractory to their last prior therapy and those who were not refractory, overall survival was significantly longer and response rate was significantly higher on the bortezomib arm. 
Tako pri bolnikih s plazmocitomom, odpornim na zadnje zdravljenje, kot pri tistih, ki so se odzvali na zdravljenje, je bilo celokupno preživetje v skupini, ki je prejemala bortezomib, statistično pomembno daljše in odziv na zdravljenje je bil statistično pomembno boljši.
Serious adverse reactions uncommonly reported during treatment with bortezomib include cardiac failure, tumour lysis syndrome, pulmonary hypertension, posterior reversible encephalopathy syndrome, acute diffuse infiltrative pulmonary disorders and rarely autonomic neuropathy. 
Med zdravljenjem z bortezomibom so občasno poročali o resnih neželenih učinkih: srčno popuščanje, sindrom tumorske lize, pljučna hipertenzija, sindrom reverzne posteriorne encefalopatije, akutna difuzna infiltracijska pljučna stanja, in redko o avtonomni nevropatiji.
The median OS was 30.8 months (95% CI; 25.2-36.5 months) for the bortezomib monotherapy patients and 33.0 months (95% CI; 28.9-37.1 months) for the bortezomib plus pegylated liposomal doxorubicin combination therapy patients. 
Za bolnike, zdravljene samo z bortezomibom je bilo mediano OS 30,8 mesecev (95 % IZ; 25,2-36,5 mesecev), za bolnike, zdravljene z bortezomibom v kombinaciji s pegiliranim liposomskim doksorubicinom pa 33,0 mesecev (95 % IZ; 28,9 - 37,1 meseca).
In the 6-month rat study, degenerative effects in both the testes and the ovary have been observed. 
V 6-mesečni raziskavi na podganah so opazili degenerativne učinke tako na testise kot na ovarije, zato je verjetno, da bi bortezomib lahko vplival na plodnost samcev ali samic.
Patient demographic and baseline disease characteristics were similar between the treatment groups. 
Bolniki v obeh skupinah so imeli podobne demografske značilnosti in značilnosti bolezni ob začetku preskušanja.
Bortezomib Hospira is for single use only. 
Zdravilo Bortezomib Hospira je samo za enkratno uporabo.
Hepatitis B Virus (HBV) reactivation and infection 
Reaktivacija in okužba z virusom hepatitisa B (HBV) Limfom plaščnih celic
Bortezomib exposure is increased in patients with moderate or severe hepatic impairment; these patients should be treated with Bortezomib Hospira at reduced doses and closely monitored for toxicities (see sections 4.2 and 5.2). 
Pri bolnikih z zmerno ali hudo jetrno okvaro je izpostavljenost bortezomibu povečana, zato je treba te bolnike zdraviti z manjšimi odmerki zdravila Bortezomib Hospira in pri njih skrbno spremljati morebitni pojav toksičnosti (glejte poglavji 4.2 in
In the Phase III study in patients with previously untreated multiple myeloma, the overall incidence of herpes zoster reactivation was more common in patients treated with bortezomib+melphalan+prednisone compared with melphalan+prednisone (14% versus 4% respectively). 
V preskušanju faze III, pri bolnikih s predhodno nezdravljenim diseminiranim plazmocitomom, je bila splošna pojavnost reaktivacije virusa herpes zoster pri bolnikih hkrati zdravljenih z bortezomibom, melfalanom in prednizonom pogostejša, kot pri bolnikih hkrati zdravljenih z melfalanom in prednizonom (14 % v primerjavi s 4 %).
Uncommon Infection*, Bacterial infections*, Viral infections*, Sepsis (inc septic shock)*, Bronchopneumonia, Herpes virus infection*, Meningoencephalitis herpetic 
Občasni okužba*, bakterijske okužbe*, virusne okužbe*, sepsa (vključno s septičnim šokom)*, bronhopnevmonija, okužba z virusom herpes*, herpetični meningoencefalitis
In patients with advanced myeloma the severity of thrombocytopenia was related to pre-treatment platelet count: for baseline platelet counts < 75,000/μl, 90% of 21 patients had a count ≤ 25,000/μl during the study, including 14% < 10,000/μl; in contrast, with a baseline platelet count > 75,000/μl, only 14% of 309 patients had a count ≤ 25,000/μl during the study. 
Pri bolnikih, z napredovalim plazmocitomom, je bila resnost trombocitopenije povezana s številom trombocitov pred zdravljenjem (90 % od 21 bolnikov, ki so imeli začetno število trombocitov < 75.000/μl, je med preskušanjem imelo število trombocitov ≤ 25.000/μl (vključno s 14 % bolnikov, ki so imeli število trombocitov < 10.000/μl).
Table 3: Posology modifications during subsequent cycles of Bortezomib Hospira therapy in combination with melphalan and prednisone 
Preglednica 3: Prilagajanje odmerkov med kasnejšimi cikli zdravljenja z zdravilom Bortezomib Hospira v kombinaciji z melfalanom in prednizonom
Response Rate at 8 cycles n (%) ORR (CR+PR) p-value 
Stopnja odziva v 8. ciklu n (%) ORR (CR+PR) vrednost p
• Induction Transplant Regimens Graph. 
• Diagram režima uvajanja zdravljenja pred transplantacijo
TTP, months (95% CI) 
TTP (dnevi [95 % IZ])
Neoplasm malignant, Leukaemia plasmacytic, Renal cell carcinoma, Mass, Mycosis fungoides, Neoplasm benign* 
Redki maligne neoplazme, plazmocitna levkemija, karcinom ledvičnih celic, novotvorba, fungoidna mikoza, benigne neoplazme
* Grouping of more than one MedDRA preferred term. 
* združitev več priporočenih terminov po MedDRA.
Table 10: Incidence of peripheral neuropathy in study LYM-3002 by toxicity and treatment discontinuation due to peripheral neuropathy 
Preglednica 10: Pojavnost periferne nevropatije v preskušanju LYM-3002 glede na stopnjo toksičnosti in prekinitev zdravljenja zaradi periferne nevropatije BR-CAP (n = 240)
1, 4, 8, and 11, followed by a 17-day rest period from day 12 to day 28), dexamethasone (40 mg administered orally on days 1 to 4 and days 8 to 11), and thalidomide (administered orally at 50 mg daily on days 1-14, increased to 100 mg on days 15-28 and thereafter to 200 mg daily). 
V vsakem ciklu so prejeli bortezomib (1.3 mg/m2 dvakrat na teden na 1., 4., 8., in 11. dan, čemur je sledil 17-dnevni premor od 12. do 28. dne), deksametazon (40 mg peroralno na 1. do 4. dan in 8. do 11. dan) in talidomid (50 mg na dan peroralno na 1. do 14. dan, povečan odmerek 100 mg na 15. do 28. dan in potem povečan odmerek 200 mg na dan).
Clinical efficacy in relapsed or refractory multiple myeloma The safety and efficacy of bortezomib (injected intravenously) were evaluated in 2 studies at the recommended dose of 1.3 mg/m2: a Phase III randomised, comparative study (APEX), versus dexamethasone (Dex), of 669 patients with relapsed or refractory multiple myeloma who had received 1-3 prior lines of therapy, and a Phase II single-arm study of 202 patients with relapsed and refractory multiple myeloma, who had received at least 2 prior lines of treatment and who were progressing on their most recent treatment. 
Klinična učinkovitost pri ponovitvi ali diseminiranem plazmocitomu, odpornem na zdravljenje Varnost in učinkovitost bortezomiba (injiciran intravensko) v priporočenem odmerku 1,3 mg/m2 so ovrednotili v dveh preskušanjih: v randomiziranem, primerjalnem (primerjava z deksametazonom (Dex)) preskušanju faze III (APEX) pri 669 bolnikih s ponovitvijo ali diseminiranim plazmocitomom, odpornim na zdravljenje, ki so pred tem že prejeli 1 do 3 vrste zdravljenja ter v enoskupinskem preskušanju faze II pri 202 bolnikih s ponovitvijo ali diseminiranim plazmocitomom, odpornim na zdravljenje, ki so pred tem že prejeli najmanj 2 vrsti zdravljenja in je bolezen ob zadnji vrsti zdravljenja napredovala.
When bortezomib is given together with pegylated liposomal doxorubicin, you will receive bortezomib intravenously or subcutaneously as a 21-day treatment cycle and pegylated liposomal doxorubicin 30 mg/m is given on day 4 of the bortezomib 21-day treatment cycle as an intravenous infusion after the bortezomib injection. 
Če boste prejeli bortezomib skupaj s pegiliranim liposomskim doksorubicinom, boste prejeli bortezomib v veno ali v podkožje v 21-dnevnem ciklu zdravljenja in pegilirani liposomski doksorubicin v odmerku 30 mg/m v obliki intravenske infuzije na 4. dan 21-dnevnega cikla zdravljenja, po injekciji bortezomiba.
Patients should be closely monitored when given Bortezomib Hospira in combination with potent CYP3A4-inhibitors. 
Bolnike, ki prejemajo zdravilo Bortezomib Hospira v kombinaciji z močnimi zaviralci encima CYP3A4, je treba skrbno spremljati.
When Bortezomib Hospira is given in combination with other medicinal products, the Summary of Product Characteristics of these other medicinal products must be consulted prior to initiation of treatment with Bortezomib Hospira. 
Kadar se zdravilo Bortezomib Hospira uporablja v kombinaciji z drugimi zdravili, je treba prebrati Povzetke glavnih značilnosti teh zdravil pred začetkom zdravljenja z zdravilom Bortezomib Hospira.
However, the chemical and physical in-use stability of the reconstituted solution has been demonstrated for 8 hours at 5°C and 25°C stored in the original vial and/or a syringe. 
Kemična in fizikalna stabilnost rekonstituirane raztopine sta bili dokazani za 8 ur pri temperaturah 5°C in 25 °C, če jo shranjujemo v originalni viali in/ali injekcijski brizgi.
#, Bacteraemia (inc staphylococcal), Hordeolum, Influenza, Cellulitis, Device related infection, Skin infection*, Ear infection*, Staphylococcal infection, Tooth infection* 
#, bakteriemija (vključno s stafilokokno), hordeol, gripa, celulitis, z uporabo katetra povezana okužba, okužba kože*, ušesna okužba*, okužba s stafilokoki, okužba zob*
Patients should be monitored at regular intervals for any new or worsening neurological symptoms or signs that may be suggestive of PML as part of the differential diagnosis of 
Kot del diferencialne diagnoze težav CŽS je pri bolnikih potrebno redno spremljanje glede pojavov novih ali poslabšanja nevroloških simptomov ali znakov, ki bi lahko nakazovali na PML.
In subsequent doses, mean maximum observed plasma concentrations ranged from 67 to 106 ng/ml for the 1.0 mg/m2 dose and 89 to 
Pri ponavljajočih odmerkih so bile povprečne vrednosti največjih plazemskih koncentracij v razponu 67 do 106 ng/ml pri odmerku 1,0 mg/m2 in 89 do 120 ng/ml pri odmerku 1,3 mg/m
Response Rate at 4 cycles n (%) ORR (CR+PR) p-value 
Stopnja odziva v 4. ciklu n (%) ORR (CR+PR) vrednost p
• If prolonged Grade 4 neutropenia or thrombocytopenia, or thrombocytopenia with bleeding is observed in the previous cycle 
• Če je bila v prejšnjem ciklu zdravljenja opažena dolgotrajna nevtropenija 4. stopnje, trombocitopenija ali trombocitopenija in krvavitev
Bortezomib Hospira contains the active substance bortezomib, a so-called ‘proteasome inhibitor'. 
Zdravilo Bortezomib Hospira vsebuje učinkovino bortezomib, ki je t.i. zaviralec proteasomov.
• Bortezomib Hospira 1 mg, 2.5 mg, 3 mg and 3.5 mg can be administered both intravenously and subcutaneously 
• Zdravilo Bortezomib Hospira 1 mg, 2,5 mg, 3 mg in 3,5 mg se daje intravensko in subkutano.
Rituximab at 375 mg/m2 , cyclophosphamide at 750 mg/m2 and doxorubicin at 50 mg/m2. 
375 mg/m2 rituksimaba, 750 mg/m ciklofosfamida in 50 mg/m doksorubicina.
T 100 mg a 
T 100 mg na dan na dan
c p-value 
vrednost p
In study MMY-3010 induction treatment with bortezomib combined with thalidomide and dexamethasone [BTDx, n=130] was compared to thalidomide-dexamethasone [TDx, n=127]. 
V preskušanju MMY-3010 so primerjali uvajalno zdravljenje z bortezomibom v kombinaciji s talidomidom in deksametazonom [BTDx, n = 130] s kombinacijo talidomid-deksametazon [TDx, n = 127].
The primary efficacy endpoints of the study were post-induction and post-transplant response rates (CR+nCR). 
Primarni opazovani dogodek učinkovitosti je bila stopnja odziva po uvedbi zdravljenja in po presaditvi (CR+nCR).
• dosing instructions and examples: how to calculate the body surface area of a patient and the volume of reconstituted Bortezomib Hospira (both IV and SC use) required for different body surface areas. 
• Navodila za odmerjanje s primeri: kako se izračuna telesna površina bolnika in volumen rekonstituiranega zdravila Bortezomib Hospira (za i.v.
In B-ALL patients with relapse 18-36 months from diagnosis (n = 33) the CR rate was 79% (95% CI: 61, 91) and the 4-month event free survival rate was 73% (95% CI: 54, 85). 
Pri bolnikih z B-celično ALL in ponovitvijo po 18-36 mesecev po diagnozi (n = 33) je bil delež popolnih odzivov 79 % (95 % IZ: 61, 91) in delež 4-mesečnega preživetja bolnikov brez dogodkov 73 % (95 % IZ: 54, 85).
Peripheral neuropathy included the preferred terms: peripheral sensory neuropathy, neuropathy peripheral, peripheral motor neuropathy, and peripheral sensorimotor neuropathy 
Periferna nevropatija vključuje priporočene termine: periferna senzorična nevropatija, periferna nevropatija, periferna motorična nevropatija in periferna senzomotorična nevropatija.
• to report any adverse event, or medication error experienced with the administration of Bortezomib Hospira 1 mg, 2.5 mg, 3 mg and 3.5 mg. 
• Pomembnost poročanja o kakršnemkoli neželenem učinku ali napakah pri dajanju zdravila Bortezomib Hospira 1 mg, 2,5 mg, 3 mg in 3,5 mg.
Grade ≥ 3 non-haematological toxicities considered to be related to Bortezomib Hospira 
Nehematološka toksičnost stopnje ≥ 3 povezana z uporabo zdravila Bortezomib Hospira
CR+nCR+VGPR+PR % (95% CI) 
CR+nCR+VGPR+PR% (95 % IZ)
For bortezomib-related neuropathic pain and/or peripheral neuropathy, hold and/or modify Bortezomib Hospira as outlined in Table 1. 
V primeru nevropatske bolečine in/ali periferne nevropatije povezane z bortezomibom ukinite in/ali prilagodite odmerek zdravila Bortezomib Hospira, kot je opisano v preglednici 1.
Table 7: Adverse reactions in patients with multiple myeloma treated with Bortezomib in clinical trials, and all post-marketing adverse reactions regardless of indication System Organ Class 
Preglednica 7: Neželeni učinki pri bolnikih z diseminiranim plazmocitomom, zdravljenih z zdravilom Bortezomib v kliničnih preskušanjih in v obdobju trženja, neodvisno od indikacije
The primary efficacy endpoint was TTP while the secondary efficacy endpoints were OS and ORR (CR+PR), using the European Group for Blood and Marrow Transplantation (EBMT) criteria. 
Po kriterijih Evropske skupine za transplantacijo kostnega mozga (EBMT - European Group for Blood and Marrow Transplantation) je bil primarni opazovani dogodek glede učinkovitosti TTP, sekundarna opazovana dogodka pa OS in ORR (CR+PR).
• Weight loss 
• izguba teka
The CR rate in first-relapsed T-cell ALL patients (n = 22) was 68% (95% CI: 45, 86) and the 4-month event free survival rate was 67% (95% CI: 42, 83). 
Delež popolnih odzivov pri prvih bolnikih s T-celično ALL (n = 22) je bil 68 % (95 % IZ: 45, 86), delež 4-mesečnega preživetja bolnikov brez dogodkov pa 67 % (95 % IZ: 42, 83).
Therefore, platelet counts should be monitored prior to each dose of Bortezomib Hospira. 
Zato je treba pred dajanjem vsakega odmerka zdravila Bortezomib Hospira določiti število trombocitov.
If you have not been treated before for mantle cell lymphoma, you will receive bortezomib intravenously or subcutaneously together with the medicines rituximab, cyclophosphamide, doxorubicin and prednisone. 
Če vam limfoma plaščnih celic še niso zdravili, boste bortezomib prejeli v veno, skupaj z rituksimabom, ciklofosamidom, doksorubicinom in prednizonom.
In patients developing PRES, Bortezomib Hospira should be discontinued. 
Če se pri bolniku pojavi PRES, je treba zdravljenje z zdravilom Bortezomib Hospira prekiniti.
Skin reaction, Jessner's lymphocytic infiltration, Palmar-plantar erythrodysaesthesia syndrome, Haemorrhage subcutaneous, Livedo reticularis, Skin induration, Papule, Photosensitivity reaction, Seborrhoea, Cold sweat, Skin disorder NOS, Erythrosis, Skin ulcer, Nail disorder 
Redki kožna reakcija, Jessnerjeva limfocitna infiltracija, sindrom palmarno-plantarne eritrodisestezije, podkožna krvavitev, livedo retikularis, zatrdlina kože, papula, fotosenzitivna reakcija, seboreja, hladen znoj, bolezni kože NOS, eritroza, kožna razjeda, bolezni nohtov
Common Herpes zoster (inc disseminated & ophthalmic), Pneumonia*, Herpes simplex*, Fungal infection* 
Pogosti herpes zoster (vključno z diseminiranim in očesnim), pljučnica*, herpes simpleks*, glivična okužba*
CR+nCR+ PR+MR Median duration Days (months) Time to response CR+PR (days) 
Mediano trajanje odziva dnevi (meseci) Čas do odziva CR + PR (dnevi)
1.3 The reconstituted product is preservative free and should be used immediately after preparation. 
Rekonstituirana raztopina ne vsebuje konzervansov in jo je treba porabiti takoj po pripravi.
Bortezomib Hospira should not be administered intrathecally. 
Zdravila Bortezomib Hospira se ne sme dajati intratekalno.
However, the dose-normalised mean AUC values were increased by approximately 60% in patients with moderate or severe hepatic impairment. 
Pri bolnikih z zmerno ali hudo okvaro jeter pa so se vrednosti srednje, na odmerek normalizirane AUC povečale za 60%.